Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors
Open Access
- 31 May 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (11), 5990
- https://doi.org/10.3390/ijms22115990
Abstract
Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair deficiency are hypermutated and have a good response towards immune-checkpoint inhibitors (ICIs), including α-PD-L1 antibodies. However, in most cases, resistance mechanisms evolve. To improve outcomes and prevent resistance development, combination approaches are warranted. Herein, we applied a combined regimen with an α-PD-L1 antibody and gemcitabine in a preclinical tumor model to activate endogenous antitumor immune responses. Mlh1−/− mice with established gastrointestinal tumors received the α-PD-L1 antibody (clone 6E11; 2.5 mg/kg bw, i.v., q2wx3) and gemcitabine (100 mg/kg bw, i.p., q4wx3) in mono- or combination therapy. Survival and tumor growth were recorded. Immunological changes in the blood were routinely examined via multi-color flow cytometry and complemented by ex vivo frameshift mutation analysis to identify alterations in Mlh1−/−-tumor-associated target genes. The combined therapy of α-PD-L1 and gemcitabine prolonged median overall survival of Mlh1−/− mice from four weeks in the untreated control group to 12 weeks, accompanied by therapy-induced tumor growth inhibition, as measured by [18F]-FDG PET/CT. Plasma cytokine levels of IL13, TNFα, and MIP1β were increased and also higher than in mice receiving either monotherapy. Circulating splenic and intratumoral myeloid-derived suppressor cells (MDSCs), as well as M2 macrophages, were markedly reduced. Besides, residual tumor specimens from combi-treated mice had increased numbers of infiltrating cytotoxic T-cells. Frameshift mutations in APC, Tmem60, and Casc3 were no longer detectable upon treatment, likely because of the successful eradication of single mutated cell clones. By contrast, novel mutations appeared. Collectively, we herein confirm the safe application of combined chemo-immunotherapy by long-term tumor growth control to prevent the development of resistance mechanisms.Funding Information
- Deutsche Forschungsgemeinschaft (MA5799/2-2)
This publication has 58 references indexed in Scilit:
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabClinical Cancer Research, 2016
- Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesOncotarget, 2015
- Clinically feasible approaches to potentiating cancer cell-based immunotherapiesHuman Vaccines & Immunotherapeutics, 2015
- Molecular Pathways: The Immunogenic Effects of Platinum-Based ChemotherapeuticsClinical Cancer Research, 2014
- Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity SetOncoImmunology, 2014
- Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortiumEuropean Journal of Cancer, 2014
- IRF5 Is a Specific Marker of Inflammatory MacrophagesIn VivoMediators of Inflammation, 2013
- Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigeneticsCarcinogenesis: Integrative Cancer Research, 2007
- Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effectsCancer Biology & Therapy, 2007
- Clonogenic assay of cells in vitroNature Protocols, 2006